Cellular immunotherapies and immune cell depleting therapies in inflammatory bowel diseases: the next magic bullet?

Blue shape

You might also be interested in...

October 24, 2025

Scaling Smarter: a Case Study in Overcoming Cell Therapy Manufacturing & Regulatory Hurdles

View

View

October 15, 2025

Tr1X Announces FDA Clearance of IND Application for TRX319, a First-in-Class Allogeneic CAR-Tr1 Treg Cell Therapy for Progressive Multiple Sclerosis, and $50 Million in Additional Financing

View

View

April 4, 2025

Tr1X Awarded $8 Million CIRM Grant to Support TRX103 Phase 1/2a Clinical Trial for Graft-Versus-Host Disease

View

View